- In January 2025, Gilead Sciences announced the commercial launch of its next-generation CAR-T cell therapy, Yescarta (axicabtagene ciloleucel), in the European Union following the receipt of a CE Mark. This innovative therapy treats relapsed or refractory large B-cell lymphoma (LBCL), providing a promising treatment option for patients who have failed other therapies. Yescarta’s advanced design allows for enhanced T-cell expansion and a more targeted approach to fighting blood cancers, improving patient outcomes by minimizing side effects
- In October 2024, Bristol-Myers Squibb (BMS) presented new data at the ASH 2024 (American Society of Hematology) meeting on its Immuno-Oncology pipeline, including Opdivo (nivolumab) and Reblozyl (luspatercept) for myelodysplastic syndromes (MDS) and multiple myeloma. These treatments show significant improvements in response rates and overall survival, positioning BMS at the forefront of hematologic cancer treatments
- In September 2024, Novartis presented promising findings at ASH 2024 for Kymriah (tisagenlecleucel), a CAR-T cell therapy, in treating acute lymphoblastic leukemia (ALL). The data demonstrated sustained long-term remission in both pediatric and adult patients, marking a significant step in the potential for gene therapies to change the treatment landscape for hematologic cancers
- In September 2024, AbbVie launched its next-generation targeted therapy for chronic lymphocytic leukemia (CLL), Venclexta (venetoclax). The combination of venetoclax with rituximab showed substantial improvements in survival rates for patients with relapsed/refractory CLL, highlighting AbbVie’s continued innovation in the field of hematologic malignancies
